
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.
Nuvation Bio revenue
Nuvation Bio's annual revenue was $62.9M in December 2025 (Stock Analysis). That is up 699% from $7.9M a year earlier.
All 2 revenue readings, with sources
| As of | Revenue | Source |
|---|---|---|
| Dec 2024 | $7.9M | Stock Analysis |
| Dec 2025 | $62.9M | Stock Analysis |
Nuvation Bio market cap
Nuvation Bio is a public company. Its market capitalisation was $2B in September 2026.
Nuvation Bio CEO
David Hung is CEO of Nuvation Bio.
- David HungCEO
Nuvation Bio FAQ
What is Nuvation Bio's revenue?
Nuvation Bio's annual revenue was $62.9M in December 2025, according to Stock Analysis.
Is Nuvation Bio publicly traded?
Yes. Nuvation Bio is a public company, with a market capitalisation of $2B in September 2026.
Who is the CEO of Nuvation Bio?
David Hung is the CEO of Nuvation Bio.
Categories
How this page is sourced
2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Nuvation Bio? Join the podcast